Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid. Statistically significant increases in time to subjective and objective progression were recorded in favor of the combination treatment. No differences in time to death by cancer or overall death were recorded. The clinical significance of these differences will be reassessed once additional follow-up is available and further analysis of the overall clinical material has been carried out.
Keuppens
F
F
AZ Middelheim, Antwerp, Brussels, Belgium.
Denis
L
L
Smith
P
P
Carvalho
A P
AP
Newling
D
D
Bond
A
A
Sylvester
R
R
De Pauw
M
M
Vermeylen
K
K
Ongena
P
P
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005485:Flutamide / Q000008:administration & dosage; D017273:Goserelin; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011877:Radionuclide Imaging; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
D017273:Goserelin; D005485:Flutamide; D002064:Buserelin